Semorinemab
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
2
Sites
152
Countries
13
Endpoints
57
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 57 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 23 of 57 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
6
6
5
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03289143A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease | Semorinemab Alzheimer’s disease | prodromal AD | Ph 2 | Terminated | 133 | Jan 2021 | 6 | results |
| NCT03828747A Study of Semorinemab in Patients With Moderate Alzheimer's Disease | Semorinemab Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 49 | Jul 2021 | 3 | results |
| NCT02820896A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease | Semorinemab Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 1 | Jun 2017 | 1 |
Showing 1-3 of 3 trials